Cognition Therapeutics, Inc. (CGTX)

Overview

Cognition Therapeutics, Inc. is a small clinical-stage biopharmaceutical company based in Purchase, New York, focused on small-molecule therapeutics for age-related degenerative diseases of the central nervous system and retina, most notably Alzheimer's disease and dementia with Lewy bodies. The company is tiny by headcount — just 14 full-time employees, eight of them in R&D — and trades on the Nasdaq Capital Market as a micro-cap, with a non-affiliate market value of only about $18.2 million as of mid-2025 and roughly 89.4 million shares outstanding as of March 2026. Cognition's research has been substantially underwritten by government grants: it has received approximately $171 million in cumulative funding from the National Institute on Aging (part of the NIH), with about $35.7 million of committed NIA funds still available as of year-end 2025 to support ongoing trial costs — an unusually large non-dilutive funding base for a company of its size.

What They Do & How They Make Money

Cognition does not sell any products; its business is entirely pre-revenue drug development funded by a mix of NIA grant dollars and public equity capital. Its lead and only clinically advanced candidate is zervimesine (CT1812), an orally delivered small molecule designed to block toxic protein oligomers — beta-amyloid and alpha-synuclein — from binding to synapses on neurons, a mechanism distinct from the monoclonal-antibody approaches (like Leqembi and Kisunla) that dominate current Alzheimer's treatment. By targeting the sigma-2 receptor complex rather than directly clearing amyloid plaque, zervimesine is positioned as an oral, potentially better-tolerated alternative or complement to infused antibody therapies.

Pipeline & Clinical Status

The SHINE and SHIMMER readouts are the most important data points to date, giving zervimesine a differentiated efficacy signal in both Alzheimer's and the underserved dementia-with-Lewy-bodies population, where few approved disease-modifying treatments exist.

Competitors

Cognition's 10-K identifies its primary competitive threat as the currently approved monoclonal antibody therapies for Alzheimer's disease — Eisai's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) — both of which are infused, amyloid-clearing treatments with substantially greater commercial infrastructure and physician awareness behind them. In dementia with Lewy bodies, the competitive landscape is comparatively thin, since the company notes there are currently limited approved disease-modifying treatment options, a gap zervimesine could fill if its Phase 2 results hold up in larger trials.

Competitive Position

Cognition's core strength is a differentiated, oral, small-molecule mechanism with encouraging — though still early — efficacy signals across two distinct neurodegenerative indications, backed by an unusually deep well of non-dilutive NIH/NIA funding that reduces near-term dependence on capital markets. That funding, combined with its sub-$20 million market capitalization, suggests the market is deeply skeptical of the company's ability to advance zervimesine to approval and commercialization given its tiny size (14 employees) relative to well-capitalized competitors like Eisai and Eli Lilly, which can outspend Cognition many times over on trials, regulatory affairs, and eventual sales infrastructure. There is no approved product, no revenue, and no manufacturing or distribution capability today. The company's path forward depends on advancing START (MCI/early AD) and DLB data toward pivotal trials, likely requiring a much larger capital raise or a pharma partnership to fund Phase 3 development and eventual commercialization.

Sources

• Cognition Therapeutics, Inc. 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
• Cognition Therapeutics, Inc. (CGTX) Stock Overview — StockAnalysis.com